Friday, August 05, 2022
Avivagen Inc. (VIVXF)
AB Vista Gets on the Board
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
A Pathway Into Brazil. Avivagen’s management announced Wednesday that the Company has received a 1.2 tonne order of OxC-beta from AB Vista that will be shipped for use in Brazil. It will be used for ongoing trials with several large poultry and cattle producers. We believe that this is a stepping stone in Avivagen’s aggressive marketing in OxC-beta, as the order represents increased awareness of the product.
Brazil Market. As a reminder, AB Vista is the exclusive distribution partner for Avivagen in the United States, Brazil, and Thailand. Brazil is the third largest for animal feed behind China and the U.S., and produced 80.1mmt in 2021. We anticipate more deals coming from the Brazil market, as AB Vista has existing relationships and distribution partnerships it can use to further sales of the OxC-beta product….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
